Immunomodulation therapies for heart failure lack broad efficacy across all subtypes, though they have proven effective in cases due to viral infections.
While early trials of anti-inflammatory therapies in general heart failure have been disappointing, targeted immunomodulation in specific subtypes like viral myocarditis shows therapeutic promise.
INTRODUCTION: The review deals with inflammation in heart failure (HF). Many data show that systemic inflammation is frequent in HF and implicate that inflammation contributes to damage and dysfunction of the cardiovascular system. Areas Covered: Experimental data have been mainly obtained in acute laboratory animal models. It is questionable whether animals' data can be translated into clinical settings with patients with chronic HF who have concomitant pathologies. The idea of a common inflammatory pathway that characterizes all different forms of clinical HF is unrealistic. It seems realistic that inflammation differs in non-cardiac and cardiac diseases. Research therapeutic options address the use of inhibitors of cytokines, of agents antagonizing oxidative stress, of MMP and of PI3K signaling pathways. Expert Opinion: Considering the many unknowns in our knowledge it is not surprising that early trials aimed to antagonize inflammation in HF have been disappointing. We are far away from having solid therapeutic schedules to use immunomodulation in all subtypes of HF. However, modern trials on HF due to virus infections have proven that immunomodulation is therapeutically effective. We should wisely use the known facts and accept that we have many unknowns. By appropriate selection of the subtypes of HF we may be able to find the appropriate therapy against inflammation in HF.
Cocco et al. (Thu,) conducted a review in Heart failure. Immunomodulation was evaluated. Immunomodulation therapies for heart failure lack broad efficacy across all subtypes, though they have proven effective in cases due to viral infections.